On October 14, 2024, Health Innovation Manchester and The University of Manchester unveiled a significant strategic partnership with Eli Lilly and Company to initiate a five-year real-world evidence study, known as SURMOUNT-REAL UK. This collaboration was announced during the UK Government’s International Investment Summit and is subject to relevant approvals.
Study Overview
The SURMOUNT-REAL UK study will evaluate the real-world effectiveness of tirzepatide, a medication aimed at weight loss, diabetes prevention, and the prevention of obesity-related complications in adults with obesity. The primary goal of the study is to enhance the global evidence base on the long-term impacts of weight loss medications. The findings are expected to inform the UK’s care pathway for treating obesity.
Key Objectives
The study aims to collect comprehensive data on several critical areas, including:
- Long-term efficacy and safety of tirzepatide compared to usual care
- Impact on obesity and diabetes incidence
- Healthcare resource utilization
- Health-related quality of life
- Changes in participants’ employment status and sick days from work
Statements from Key Stakeholders
Andy Burnham, Mayor of Greater Manchester, emphasized the city’s reputation as a hub for health and life sciences innovation. He noted that the trial’s results could significantly influence global obesity treatment strategies, leveraging Greater Manchester’s robust health data assets and research capabilities.
Professor Martin Rutter, principal investigator for the study, stated, “This five-year real-world study aims to demonstrate the long-term efficacy and safety profile of tirzepatide in a primary care setting. It will specifically quantify the medicine’s long-term effects on obesity, diabetes incidence, and obesity-related complications, as well as its impacts on employment and health economic outcomes.”
Professor Rachel Batterham, Senior Vice President for International Medical Affairs at Lilly, expressed excitement about the collaboration, highlighting Lilly’s commitment to improving lives through partnerships that address complex health challenges like obesity.
Ben Bridgewater, CEO at Health Innovation Manchester, noted the potential of this landmark partnership to enhance the understanding of how innovative treatments can impact long-term health outcomes for individuals with obesity.
Mark Britnell, Chair of Health Innovation Manchester, remarked on Greater Manchester’s strengths in life sciences and digital innovation, which position the region as a leader in health innovation.
Mark Fisher, CEO of the NHS Greater Manchester Integrated Care Board, highlighted the pressing issue of obesity in the region, with approximately 600,000 adults affected, many of whom suffer from related health conditions. He stressed the importance of collaborative efforts with industry to address these challenges.
Jonathan Wogel, CEO of NorthWest EHealth, emphasized the significance of this study for the UK clinical trials industry, showcasing how technology and health data can be integrated to improve research efficiency and patient care.
Conclusion
The SURMOUNT-REAL UK study represents a pivotal step in understanding the long-term effects of tirzepatide and its potential role in transforming obesity treatment strategies. With the collaborative efforts of Health Innovation Manchester, The University of Manchester, Eli Lilly, and local health organizations, this research aims to set a new standard for obesity management in the UK and beyond.
Related Topic:
How To Get Weight Loss Surgery Covered
